The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists

✍ Scribed by Vibeke Guldbrand Rasmussen; Karen Østergaard; Erik Dupont; Steen Hvitfeldt Poulsen

• Publisher: John Wiley and Sons
• Year: 2011
• Tongue: English
• Weight: 217 KB
• Volume: 26
• Category: Article
• ISSN: 0885-3185
• DOI: 10.1002/mds.23470

✦ Synopsis

Abstract

Objectives:

Several observational studies suggest an association between treatment with ergoline‐derived dopamine agonists and valvular regurgitation. In this article, we present an overview of the literature and conduct a meta‐analysis.

Methods:

Observational studies addressing the frequency of moderate or severe valvular regurgitation among ergoline‐treated patients with Parkinson's disease were considered for a meta‐analysis. Pooled risk estimates and the risk of increased pulmonary artery pressure were calculated.

Results:

The pooling of data from well‐designed observational studies documented that both pergolide (RR = 3.05 [1.71–5.44]) and cabergoline (RR = 6.38 [3.17–12.81]) represent a substantially increased risk of developing moderate to severe valvular regurgitation. In addition, pergolide, but not cabergoline, was associated with an increase in pulmonary artery pressure.

Conclusions:

The present meta‐analysis confirmed a statistically significant association between pergolide and cabergoline treatment and the risk of moderate to severe valvular regurgitation. An association between bromocriptine and valvular regurgitation cannot be entirely ruled out. © 2011 Movement Disorder Society